aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Avilar Therapeutics, founded with a mission to revolutionize biopharmaceutical treatments, focuses on the discovery and development of extracellular protein degraders. This innovative approach targets proteins outside the cell, offering new therapeutic avenues for diseases that have been challenging to treat with traditional methods. Avilar's core technology platforms, ATAC and MTAC, are designed to harness the power of targeted protein degradation, aiming to address unmet medical needs across various disease areas.
Notable figures affiliated with Avilar Therapeutics include a distinguished team of scientific advisors and a board of directors comprising industry veterans. The company has attracted significant investment from leading venture capital firms, underscoring confidence in its groundbreaking approach. Key achievements include the development of their proprietary ATAC and MTAC platforms, which have shown promising preclinical results. Avilar's impact lies in its potential to transform the landscape of protein degradation therapies, offering hope for more effective treatments for complex diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Protein Degraders
Technology
Biotech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Avilar Therapeutics founded?
Avilar Therapeutics was founded in 2020.
Where is Avilar Therapeutics’s headquarters located?
Avilar Therapeutics’s headquarters is located in Waltham, MA, US.
When was Avilar Therapeutics’s last funding round?
Avilar Therapeutics’s most recent funding round was for $15M (USD) in February 2023.
How many employees does Avilar Therapeutics have?
Avilar Therapeutics has 20 employees as of Feb 5, 2024.
How much has Avilar Therapeutics raised to-date?
As of July 05, 2023, Avilar Therapeutics has raised a total of $75M (USD) since Feb 16, 2023.
Add Comparison
Total Raised to Date
$75M
USD
Last Update Feb 16, 2023
Last Deal Details
$15M
USD
Feb 16, 2023
Seed
Total Employees Over Time
20
As of Feb 2024
Avilar Therapeutics Address
Waltham,
Massachusetts
02451
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts